Lupin Launches Generic Depakote ER Tablets

Pharma major Lupin Limited announced the launch of the United States Food and Drug Administration (FDA) approved divalproex sodium extended-release (ER) tablets USP, 250 mg and 500 mgThe product will be manufactured at Lupin’s Nagpur facility in India.Divalproex sodium ER tablets USP, 250 mg and 500 mg, is the generic equivalent of Depakote extended release (ER) tablets, 250 mg and 500 mg, of AbbVie Inc indicated for acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features, monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures and prophylaxis of migraine headachesDivalproex sodium extended-release (ER) tablets USP had annual sales of approximately US$ 130 million in the US, according to IQVIA MAT July 2020.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!